CAJ | 학술논문

肺癌是全世界最常见的恶性肿瘤之一.近20年来,每年肺癌新病例以大约0.5%的速率在增长,目前肺癌已成为严重危害人类生命和健康的常见病.非小细胞肺癌(non-small cell lung cancer,NSCLC)是指除小细胞癌以外的所有类型的肺癌,约占所有肺癌的75%～80%.此类肺癌的治疗早期多采用以手术为主的治疗方法,中、晚期则以放、化疗为主,但是疗效并不佳,中位生存期短.近年来,以表皮生长因子酪氨酸激酶抑制剂和血管内皮生长因子抑制剂为代表的分子靶向治疗为NSCLC提供了新的治疗手段.
폐암시전세계최상견적악성종류지일.근20년래,매년폐암신병례이대약0.5%적속솔재증장,목전폐암이성위엄중위해인류생명화건강적상견병.비소세포폐암(non-small cell lung cancer,NSCLC)시지제소세포암이외적소유류형적폐암,약점소유폐암적75%～80%.차류폐암적치료조기다채용이수술위주적치료방법,중、만기칙이방、화료위주,단시료효병불가,중위생존기단.근년래,이표피생장인자락안산격매억제제화혈관내피생장인자억제제위대표적분자파향치료위NSCLC제공료신적치료수단.
Lung cancer is one of the most frequent malignancies in the world.As the new cases of lung cancer increase yearly at the rate of 0.5%during the last 20 years,lung cancer has been considered as one of the most common diseases threatening to human life and health,Non-small cell lung cancer(NSCLC) including all types of lung cancer except small cell lung cancer has a percentage of 75%-80%of total lung cancer.For patients with NSCLC,surgery remains the main treatment of choice in the early stage,while radiotherapy and chemotherapy are the main way in intermediate-advanced stage,even though the curative effect is disappointing and the median survival time is short.However,it is proposed recently that molecule targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitor and vascular endothelial growth factor receptor inhibitor contribute a new therapeutic method on NSCLC.